Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Ascenta and LLS collaborate to develop AT-406

Dec. 10, 2010

Geron obtains license to Angiochem's peptide technology and ANG-1005

Dec. 10, 2010

Preclinical data presented on antitumor candidates 4SC-202 and 4SC-207

Dec. 10, 2010

First-in-human trial supports benefits of BKT-140 in autologous transplantation for multiple myeloma

Dec. 10, 2010

CUDC-101 shows good tolerability in first-in-human trial in advanced solid tumors

Dec. 10, 2010

Development of cancer stem cell-targeting agents SL-401 and SL-501 continues

Dec. 10, 2010

Enrollment complete in phase III trial of subcutaneous Herceptin in HER2+ breast cancer

Dec. 10, 2010

ArQule evaluates ARQ-087 in models of cancer

Dec. 9, 2010

Lilly divulges new vinyl indazolyl agents with antitumor activity

Dec. 9, 2010

ArQule begins phase I trial of ARQ-736 in advanced solid tumors

Dec. 9, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 29, 2026.
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Elixirgen and Nippon Shinyaku sign EXG-7001 option agreement
BioWorld Science
Elixirgen Therapeutics Inc. has entered into an option agreement with Nippon Shinyaku Co. Ltd. for the development and commercialization of EXG-7001 for Duchenne...
Investors bet on transformative BCI tech for neuro disorders
BioWorld
An estimated $2 billion has been invested in the brain-computer interface (BCI) space in the last two years and the level of funding is expected to continue....